FinanancingATB Therapeutics raises €54m in Series A...Belgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development. more ➔
Innate Pharma SAAntibody engineeringTetraspecific B/NK cell better than T ce...Innate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL). more ➔
AdaptimmuneClinical trialsAdaptimmune nears second approval for TC...After meeting the primary endpoints of a pivotal Phase II trial, UK-based Adaptimmune Ltd. is submitting an FDA Biologics License Application for its autologous T-cell receptor therapy (TCR-T) Lete-cel … more ➔
Qiagen NVHorizion EuropePharmahungary Group participates in ambi...Pharmahungary Group has announced it will be participating in a project aiming to set up standardised methods to examine intercellular and interorgan communication via extracellular vesicles, the next … more ➔
Alentis TherapeuticsFinancingAlentis Therapeutics raises US$181.4m in...Swiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours. more ➔
BIOCOMPEGS Europe 2024Next-gen antibody formats presented at P...Biotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several … more ➔
Memorial Sloan Kettering Cancer CentreEarly cancer detectionHarbinger Health to speed up clinical ca...US spin-out of German MPI for molecular genetics, Harbinger Health Inc, has started a collaboration with Memorial Sloan Kettering Cancer Centre to turboboost recruiting for its Core-HH study. The study … more ➔
Novo NordiskCollaborationNovo Nordisk signs deal for monthly GLP-...Novo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing … more ➔
ProBioGenCancer vaccinesTransgene and ProBioGen forge partnershipThe Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccine … more ➔
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038Novo NordiskNovo’s obesity blockbuster semaglu...In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity bloc … more ➔
Innate Pharma SA
Adaptimmune
Qiagen NV
Alentis Therapeutics
BIOCOM
Memorial Sloan Kettering Cancer Centre
Novo Nordisk
ProBioGen
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038